대장암 스크리닝 및 진단 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 스크리닝별, 진단별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Colorectal Cancer Screening and Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Screening, By Diagnostics, By End User, By Region and Competition, 2020-2030F
대장암 검진 및 진단 세계 시장은 2024년 150억 8,000만 달러로 평가되었고, 2030년까지 연평균 5.34%의 성장률(CAGR)로 예측 기간 동안 206억 3,000만 달러에 이를 것으로 예상됩니다.
대장암 검진 및 진단 세계 시장은 암 예방, 조기 발견 및 진단 기술 발전에 대한 전 세계적인 인식이 높아짐에 따라 괄목할 만한 성장세를 보이고 있습니다. 특히 50세 이상의 대장암 발병률 증가로 인해 조기 및 정확한 검진법에 대한 수요가 증가하고 있습니다. 정부와 의료 기관은 정기적인 검진의 중요성을 강조하는 인식 개선 캠페인을 시작하여 검진 건수가 급증하는 데 기여하고 있습니다. 공공-민간 파트너십과 헬스케어 자금 지원 이니셔티브를 통해 진단 서비스에 대한 접근성을 확대할 수 있게 되었으며, 특히 소외된 계층의 진단 서비스를 확대할 수 있게 되었습니다. 또한 분변 면역화학검사(FIT), 분변 DNA 검사, 혈액 기반 진단과 같은 비침습적 선별검사 방법의 도입으로 선별검사가 더욱 친숙해져 더 많은 환자층에게 접근성이 높아지면서 더 많은 환자층이 검사를 받을 수 있게 되었습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
150억 8,000만 달러 |
| 시장 규모 : 2030년 |
206억 3,000만 달러 |
| CAGR : 2025-2030년 |
5.34% |
| 급성장 부문 |
병원 및 진료소 |
| 최대 시장 |
북미 |
AI 기반 대장내시경 시스템, 디지털 병리 도구, 액체 생검 기술의 개발로 검출 정확도가 향상되고 침습적 시술의 필요성이 감소하는 등 기술 혁신이 시장 전망을 재구성하는 데 중요한 역할을 하고 있습니다. 영상 진단에 머신러닝을 통합하여 임상의가 용종과 조기 종양을 보다 효과적으로 식별할 수 있도록 돕고 있습니다. 재택 및 현장 검사에 대한 관심이 높아지면서 환자 행동에도 변화가 일어나고 있으며, 더 많은 사람들이 편리한 자가 진단 도구를 선택하고 있습니다. 주요 진단 기업들은 더 높은 특이성과 민감도를 제공하는 바이오마커 기반 스크리닝 접근법을 강화하기 위한 연구에 투자하고 있으며, 이는 새로운 수익원을 창출하고 있습니다. 대장암 마커를 포함한 다중 암 검출 패널의 출현은 업계 내 혁신과 경쟁을 더욱 촉진할 것으로 예상됩니다.
주요 시장 성장 촉진요인
기술 발전
주요 시장 이슈
위양성과 과잉 진단
주요 시장 동향
비침습적 검사로의 전환
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 대장암 스크리닝 및 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 스크리닝(변검사, 대장 내시경, S상 결장경 검사 등)
- 진단(바이오마커 검사, 대장 내시경)
- 최종사용자별(병원 및 진료소, 임상 실험실 등)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 아시아태평양의 대장암 스크리닝 및 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제7장 유럽의 대장암 스크리닝 및 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 북미의 대장암 스크리닝 및 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제9장 남미의 대장암 스크리닝 및 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 대장암 스크리닝 및 진단 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 대장암 스크리닝 및 진단 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
- 업계내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
- Clinical Genomics Technologies Pty Ltd.
- Danaher Corporation
- DiaCarta, Inc
- Eiken Chemical Co., Ltd.
- Epigenomics AG
- Freenome Holdings, Inc.
- Guardant Health, Inc
- FUJIFILM Holdings Corporation
- Novigenix SA
- QuidelOrtho Corporation
- Olympus Corporation
- Lepu Medical Technology(Beijing) Co., Ltd.
제17장 전략적 제안
제18장 리서치사에 대해 & 면책사항
LSH
Global Colorectal Cancer Screening and Diagnostic Market was valued at USD 15.08 Billion in 2024 and is expected to reach USD 20.63 Billion in the forecast period with a CAGR of 5.34% through 2030. The Global Colorectal Cancer Screening and Diagnostic Market is witnessing significant growth due to increasing global awareness regarding cancer prevention, early detection, and advancements in diagnostic technologies. Rising incidence rates of colorectal cancer, particularly among individuals aged 50 and above, are propelling the demand for early and accurate screening methods. Governments and healthcare organizations are launching awareness campaigns that emphasize the importance of routine screening, contributing to a surge in testing volumes. Public-private partnerships and healthcare funding initiatives are enabling greater access to diagnostic services, especially in underserved populations. Moreover, the growing acceptance of non-invasive screening methods such as fecal immunochemical tests (FIT), fecal DNA tests, and blood-based diagnostics is making screening more accessible and acceptable to a broader patient demographic.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 15.08 Billion |
| Market Size 2030 | USD 20.63 Billion |
| CAGR 2025-2030 | 5.34% |
| Fastest Growing Segment | Hospitals and Clinics |
| Largest Market | North America |
Technological innovations are playing a vital role in reshaping the market landscape. The development of AI-based colonoscopy systems, digital pathology tools, and liquid biopsy technologies is improving detection accuracy and reducing the need for invasive procedures. Integration of machine learning in diagnostic imaging is assisting clinicians in identifying polyps and early-stage tumors more effectively. Rising interest in home-based and point-of-care testing options is also transforming patient behavior, with more individuals opting for convenient, self-administered diagnostic tools. Leading diagnostic companies are investing in research to enhance biomarker-based screening approaches that offer higher specificity and sensitivity, which is opening new revenue streams. The emergence of multi-cancer detection panels, which include colorectal cancer markers, is expected to further stimulate innovation and competition within the industry.
Key Market Drivers
Advancements in Technology
High-definition (HD) colonoscopy utilizes advanced imaging technology to provide clearer and more detailed images of the colon, enhancing the detection of precancerous polyps and early-stage colorectal cancer during procedures. According to the Centers for Disease Control and Prevention (CDC), in 2019, there were 142,462 reported cases of colon and rectum cancer in the United States, emphasizing the importance of improved detection methods.
Key Market Challenges
False Positives and Over diagnosis
False positives occur when a screening test suggests the presence of colorectal cancer or precancerous lesions when they are not actually present. False positives can cause unnecessary anxiety and stress for patients. They often lead to additional testing and procedures, which can be invasive and carry their own risks. False positives can result in increased healthcare costs due to follow-up tests and procedures. This can strain healthcare resources and increase the financial burden on individuals and healthcare systems. Experiencing a false positive result can deter individuals from participating in future screening, as they may be apprehensive about undergoing another potentially stressful experience. Over diagnosis occurs when a screening test detects a condition that, if left untreated, would not have progressed to clinical significance, or caused harm during the patient's lifetime. Over diagnosis can lead to unnecessary treatment, including surgery, chemotherapy, or radiation therapy. These interventions can have physical and psychological side effects. Treating cases that would not have caused harm can lead to overtreatment, which poses risks to the patient's overall health and quality of life.
Key Market Trends
Shift Towards Non-Invasive Tests
Non-invasive tests, such as stool-based tests or blood tests, are generally more acceptable to patients because they do not involve invasive procedures like colonoscopy. This improved patient acceptance can lead to higher screening participation rates. The avoidance of invasive procedures can reduce patient discomfort and anxiety associated with colorectal cancer screening. This can encourage individuals to undergo testing. Non-invasive tests often require minimal preparation and can be performed at home, making them more convenient for patients. This convenience can lead to higher compliance with screening recommendations. Unlike colonoscopy, which typically requires sedation or anesthesia, non-invasive tests do not involve the use of these medications, eliminating the associated risks and recovery time. Non-invasive tests are generally more cost-effective compared to invasive procedures like colonoscopy, making them an attractive option for both patients and healthcare systems. Some non-invasive tests, such as stool-based tests, can be performed more frequently, allowing for regular monitoring and early detection of changes in colorectal health. Non-invasive tests can be used to reach populations with limited access to healthcare facilities or those who may be hesitant to undergo invasive procedures. Advances in non-invasive screening technologies, such as the development of highly sensitive fecal immunochemical tests (FIT), have improved their ability to detect colorectal cancer and precancerous lesions.
Key Market Players
- Clinical Genomics Technologies Pty Ltd.
- Danaher Corporation
- DiaCarta, Inc.
- Eiken Chemical Co., Ltd.
- Epigenomics AG
- Freenome Holdings, Inc.
- Guardant Health, Inc.
- Lepu Medical Technology (Beijing) Co., Ltd.
- Novigenix SA
- FUJIFILM Holdings Corporation
- Olympus Corporation
- QuidelOrtho Corporation
Report Scope:
In this report, the Global Colorectal Cancer Screening and Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Colorectal Cancer Screening and Diagnostic Market, By Screening:
- Stool-Based Test
- Colonoscopy and Sigmoidoscopy
- Others
Colorectal Cancer Screening and Diagnostic Market, By Diagnostics:
- Biomarker Test
- Colonoscopy
Colorectal Cancer Screening and Diagnostic Market, By End User:
- Hospitals and Clinics
- Clinical Laboratories
- Others
Colorectal Cancer Screening and Diagnostic Market, By region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Colorectal Cancer Screening and Diagnostic Market.
Available Customizations:
Global Colorectal Cancer Screening and Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Colorectal Cancer Screening and Diagnostic Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Screening (Stool-Based Test, Colonoscopy and Sigmoidoscopy, others)
- 5.2.2. By Diagnostic (Biomarker Test, Colonoscopy)
- 5.2.3. By End User (Hospitals and Clinics, Clinical Laboratories, others)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. Asia Pacific Colorectal Cancer Screening and Diagnostic Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Screening
- 6.2.2. By Diagnostics
- 6.2.3. By End User
- 6.2.4. By Country
- 6.3. Asia Pacific: Country Analysis
- 6.3.1. China Colorectal Cancer Screening and Diagnostic Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Screening
- 6.3.1.2.2. By Diagnostics
- 6.3.1.2.3. By End User
- 6.3.2. India Colorectal Cancer Screening and Diagnostic Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Screening
- 6.3.2.2.2. By Diagnostics
- 6.3.2.2.3. By End User
- 6.3.3. Australia Colorectal Cancer Screening and Diagnostic Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Screening
- 6.3.3.2.2. By Diagnostics
- 6.3.3.2.3. By End User
- 6.3.4. Japan Colorectal Cancer Screening and Diagnostic Market Outlook
- 6.3.4.1. Market Size & Forecast
- 6.3.4.2. Market Share & Forecast
- 6.3.4.2.1. By Screening
- 6.3.4.2.2. By Diagnostics
- 6.3.4.2.3. By End User
- 6.3.5. South Korea Colorectal Cancer Screening and Diagnostic Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Screening
- 6.3.5.2.2. By Diagnostics
- 6.3.5.2.3. By End User
7. Europe Colorectal Cancer Screening and Diagnostic Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Screening
- 7.2.2. By Diagnostics
- 7.2.3. By End User
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Colorectal Cancer Screening and Diagnostic Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Screening
- 7.3.1.2.2. By Diagnostics
- 7.3.1.2.3. By End User
- 7.3.2. Germany Colorectal Cancer Screening and Diagnostic Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Screening
- 7.3.2.2.2. By Diagnostics
- 7.3.2.2.3. By End User
- 7.3.3. Spain Colorectal Cancer Screening and Diagnostic Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Screening
- 7.3.3.2.2. By Diagnostics
- 7.3.3.2.3. By End User
- 7.3.4. Italy Colorectal Cancer Screening and Diagnostic Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Screening
- 7.3.4.2.2. By Diagnostics
- 7.3.4.2.3. By End User
- 7.3.5. United Kingdom Colorectal Cancer Screening and Diagnostic Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Screening
- 7.3.5.2.2. By Diagnostics
- 7.3.5.2.3. By End User
8. North America Colorectal Cancer Screening and Diagnostic Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Screening
- 8.2.2. By Diagnostics
- 8.2.3. By End User
- 8.2.4. By Country
- 8.3. North America: Country Analysis
- 8.3.1. United States Colorectal Cancer Screening and Diagnostic Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Screening
- 8.3.1.2.2. By Diagnostics
- 8.3.1.2.3. By End User
- 8.3.2. Mexico Colorectal Cancer Screening and Diagnostic Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Screening
- 8.3.2.2.2. By Diagnostics
- 8.3.2.2.3. By End User
- 8.3.3. Canada Colorectal Cancer Screening and Diagnostic Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Screening
- 8.3.3.2.2. By Diagnostics
- 8.3.3.2.3. By End User
9. South America Colorectal Cancer Screening and Diagnostic Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Screening
- 9.2.2. By Diagnostics
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Colorectal Cancer Screening and Diagnostic Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Screening
- 9.3.1.2.2. By Diagnostics
- 9.3.1.2.3. By End User
- 9.3.2. Argentina Colorectal Cancer Screening and Diagnostic Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Screening
- 9.3.2.2.2. By Diagnostics
- 9.3.2.2.3. By End User
- 9.3.3. Colombia Colorectal Cancer Screening and Diagnostic Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Screening
- 9.3.3.2.2. By Diagnostics
- 9.3.3.2.3. By End User
10. Middle East and Africa Colorectal Cancer Screening and Diagnostic Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Screening
- 10.2.2. By Diagnostics
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Colorectal Cancer Screening and Diagnostic Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Screening
- 10.3.1.2.2. By Diagnostics
- 10.3.1.2.3. By End User
- 10.3.2. Saudi Arabia Colorectal Cancer Screening and Diagnostic Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Screening
- 10.3.2.2.2. By Diagnostics
- 10.3.2.2.3. By End User
- 10.3.3. UAE Colorectal Cancer Screening and Diagnostic Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Screening
- 10.3.3.2.2. By Diagnostics
- 10.3.3.2.3. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Colorectal Cancer Screening and Diagnostic Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
- 16.1. Clinical Genomics Technologies Pty Ltd.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
- 16.2. Danaher Corporation
- 16.3. DiaCarta, Inc
- 16.4. Eiken Chemical Co., Ltd.
- 16.5. Epigenomics AG
- 16.6. Freenome Holdings, Inc.
- 16.7. Guardant Health, Inc
- 16.8. FUJIFILM Holdings Corporation
- 16.9. Novigenix SA
- 16.10. QuidelOrtho Corporation
- 16.11. Olympus Corporation
- 16.12. Lepu Medical Technology (Beijing) Co., Ltd.
17. Strategic Recommendations
18. About Us & Disclaimer
